Date:1/28/2010

2010 2009 2010 2009 ---- ---- ---- ---- As Adjusted (1) As Adjusted (1) --------------- --------------- (in thousands, except per share data) Net income per diluted share on a GAAP basis $0.16 $0.09 $0.49 $0.33 -Cost of product sales 0.01 0.01 0.03 0.03 -Selling, general and administrative 0.03 0.03 0.14 0.11 -Research and development 0.01 0.01 0.06 0.05 Amortization of purchased intangibles 0.05 0.06 0.19 0.23 HeartWare transaction costs - - 0.21 - Impact of adoption of ASC 470-20 0.03 0.03 0.13 0.12 Unrealized loss on embedded derivative instrument on HeartWare loan 0.09 - - - Income tax effect of non- GAAP adjustments (0.09) (0.06) (0.28) (0.22) Convertible debt dilution impact (2) (0.02) (0.01) (0.08) (0.04) ----- ----- ----- ----- Net income per diluted share on a non-GAAP basis $0.27 $0.16 $0.89 $0.61 ===== ===== ===== ===== Shares used in calculation of net income per diluted share --GAAP 58,374 57,578 58,027 56,196 Shares used in calculation of
'/>"/>

SOURCE Thoratec Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology
5. Thoratec Schedules Fiscal 2009 Year-End Conference Call, Webcast
6. Thoratec Presentation at Canaccord Adams Conference to be Webcast
7. Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
8. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
9. Thoratec Presentation at Piper Jaffray Conference to be Webcast
10. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
11. Spherix Reports Second Quarter Earnings